ArriVent BioPharma shares collapsed by over 56% on October 6, 2026, after its lead lung cancer drug, firmonertinib, failed the Phase 3 FURVENT trial. The oral therapy did not achieve statistical significance in delaying tumor progression compared to chemotherapy in patients with EGFR exon 20 insertion-mutant non-small cell lung cancer. The failure severely damages ArriVent's prospects of competing against established treatments like Johnson & Johnson's Rybrevant in a highly competitive oncology market.
Efficacy results of the FURVENT trial
- ▪In the Phase 3 FURVENT trial, the 240mg firmonertinib dose produced a median progression-free survival of 11.0 months versus 9.5 months for chemotherapy (not statistically significant), while the 160mg dose also failed to show a meaningful benefit.
- ▪The Phase 3 FURVENT trial evaluating ArriVent BioPharma's firmonertinib as a first-line treatment for EGFR exon 20 insertion-mutant non-small cell lung cancer failed to meet its primary endpoint of progression-free survival.
- ▪ArriVent BioPharma reported secondary endpoints in the FURVENT trial, including investigator-assessed progression-free survival, confirmed objective response rates, and an immature trend toward overall survival improvement.
Safety profile of firmonertinib
- ▪The safety profile of firmonertinib in the FURVENT trial was consistent with previous clinical studies, with no new safety signals identified.
- ▪In the FURVENT trial, Grade 3 or higher treatment-emergent adverse events were 52% (240mg firmonertinib), 53% (160mg), and 55% (control), while treatment-related events were 26%, 22%, and 40%, respectively.
Impact on ArriVent BioPharma stock
- ▪ArriVent BioPharma shares fell 56.7% in pre-market trading on October 6, 2026, following the Phase 3 FURVENT trial failure, dragging the stock well below its 52-week low of $17.00.
- ▪Prior to the October 6, 2026 announcement, ArriVent BioPharma stock carried a strong consensus buy rating from multiple Wall Street firms.
EGFR exon 20 insertion-mutant lung cancer
- ▪EGFR exon 20 insertion mutations are uncommon genetic alterations that affect approximately 9% to 10% of non-small cell lung cancer patients.
- ▪Patients with non-small cell lung cancer harboring uncommon EGFR mutations, such as exon 20 insertions, have significantly lower life expectancy with available therapies.
Competitive landscape for EGFR exon 20 therapies
- ▪AstraZeneca recently agreed to pay up to $1.5 billion for rights to a marketed EGFR exon 20 therapy from Dizal Pharma.
- ▪Takeda's Exkivity, which previously targeted EGFR exon 20 insertion mutations alongside Johnson & Johnson's Rybrevant, has been withdrawn from the market.
- ▪A partnership between Taiho Oncology and Cullinan Therapeutics recently posted positive first-line clinical results with their candidate zipalertinib.
- ▪The failure of firmonertinib in the FURVENT trial impacts ArriVent BioPharma's ability to compete for market share against Johnson & Johnson's Rybrevant and other emerging therapies.
Debatable claims
- ▪Wall Street analysts bear responsibility for investor losses in high-risk biotech stocks like ArriVent
- ▪ArriVent is justified in continuing firmonertinib's development based on its secondary trial endpoints
- ▪Chemotherapy remains the most reliable first-line treatment for EGFR exon 20 lung cancer
Story comments
Loading comments…